Page 3 - XTRMCLN COVID Booklet

The New Standard for

Candida Auris – Invasive Fungal Infections are Infection Prevention
an Emerging Threat

&OLQLFDO HIĆFDF\ RI our INFECTION CONTROL PROGRAM,
iV QRW EDVHG RQ HTXLSPHQW RU FKHPLFDOV DORQH Only through a
systematic, standardized approach to LQIHFWLRQ SUHYHQWLRQ
FDQ RQH HQVXUH VLJQLĆFDQWO\ EHWWHU results. With XstreamClean’s

chemistry and end-to-end system you can:

• Improve compliance standards

• Eliminate potential failure points from human error
• Simplify the process with safer technology and chemicals

• Reduce outbreaks and it's transmission

• Boost worker happiness, success and overall well-being!

• C.auris is a deadly fungus infection. XstreamClean’s innovative technology and standardized process

Nearly 50% of patients who contract C.auris help you achieve reliable training and management RI SHUVRQQHO
DGHTXDWH FRQWDFW WLPH FRPSOLDQFH ZLWK protocols, accessibility
die within 90 days. (CDC) to surfaces, and measurable auditing through microbiological
• 90% of C.auris infections are resistant analysis.

to one anti-fungal drug, 30% are resistant
to at least two. (CDC).

On The RISE systems, putting them at greater risk for IFD's. High-risk groups include:
An increasing number of people in the U.S. have compromised immune

hospitalized patients cancer or transplant patients
patients undergoing surgery patients with chronic diseases

5DWHV RI LQYDVLYH FDQGLGLDVLV DUH GLIĆFXOW WR HVWLPDWH Candida auris (C.auris) is an emerging drug-resistant
and can vary based on time, region, and study type. IXQJXV WKDW VSUHDGV TXLFNO\ DQG KDV FDXVHG VHULRXV DQG
deadly infections in over a dozen countries.

AGE 40s 50s 60+

Still, it is clear that overall incidence and related The CDC estimates that more than one in three patients
mortality remain high – especially among older patients. in the U.S. with invasive C.auris infection will die.